Australia ATTR (Transthyretin Amyloidosis) Therapeutics Market Report 2023 to 2030

Australia ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis

$ 3999

Australia ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.

ID: IN10AURD009 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Nipun Arora

Buy Now

Australia ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis Summary

Australia ATTR (Transthyretin Amyloidosis) Therapeutics Market is valued at around $61.32 Mn in 2022 and is projected to reach $123.09 Mn by 2030, exhibiting a CAGR of 9.1% during the forecast period 2023-2030.

The body's organs and tissues are affected by this uncommon, progressive disease, which is characterised by the accumulation of aberrant proteins like mister. The disease's symptoms primarily relate to the organs affected, such as carpel syndrome in the arms, lumbar spinal stenosis in the back, vitreous opacities in the head and neck, and oedema in the feet. The two main forms of transthyretin amyloidosis are wild-type ATTR and mutated/hereditary ATTR. Major body organs like the liver, kidney, nerves, and heart are frequently impacted by it.

The Amyloidosis Foundation estimates that there are approximately 126 different genetic variations in ATTR and up to 53 types of genetic variations in hereditary amyloidosis illnesses that are not transthyretin-related. Transthyretin amyloidosis reports have indicated that approximately 10,000, or 1.1 per 100,000 people worldwide, are thought to have TTR-FAP. Patients with the disease typically fall within the 30- to 40-year-old age range. TTR-CM has also been seen to primarily affect older guys 65 years of age and older. The likelihood of a parent with the mutation passing it on to their offspring is only 50%. Tissue biopsies, genetic tests, and cardiac imaging examinations are used to make the diagnosis of transthyretin amyloidosis.

An increase in disease prevalence, an increase in the population of people with African ancestry, an increase in awareness, advancements in diagnostic techniques, enhancements in healthcare services, swift economic development in developing nations, and an increase in research and development activity are likely to drive the global transthyretin amyloidosis treatment market. Contrarily, low levels of awareness in poor nations, incorrect diagnoses of the disease, high costs of disease diagnosis and treatment, a dearth of clinical studies, and a lack of effective medications are the main obstacles holding back the market for transthyretin amyloidosis treatments.

Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and many others are global competitors in the ATTR (Transthyretin Amyloidosis) market.

Market dynamics

Market Drivers

The market for treatments for transthyretin amyloidosis is primarily driven by the existence of favourable reimbursement programmes and the expanding population. Transthyretin amyloidosis is predicted to have a higher survival rate and a better prognosis with greater research efforts aimed at creating novel diagnostic methods and multimodal therapy approaches. Industry growth is anticipated to be fueled by strategic measures done by major firms, such as raising awareness of the target conditions, such as ATTR, and the long-term advantages of available medicines. For instance, the "Heart Hero" campaign was launched by Pfizer, Inc. and the World Heart Federation in 2019. Pfizer, Inc. offers clinicians and patients resources and educational material about ATTR-CM as part of this programme. Such initiatives are anticipated to increase the early

Market Restraints

The expansion of the transthyretin amyloidosis therapy market is significantly hindered by the lack of sophisticated diagnostic facilities in underdeveloped nations. In addition, the market for ATTR (Transthyretin Amyloidosis) Therapeutics is being constrained by a lack of awareness in developing economies, disease misdiagnosis, high costs associated with disease diagnosis and treatment, a lack of clinical studies, and a lack of effective medications.

Key players

Alnylam Pharmaceuticals Pfizer Sanofi Prothena Biopharma Ionis Pharmaceuticals uniQure Catalyst Biosciences Intercept Pharmaceuticals Novartis Madrigal Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market segmentations for Australia ATTR (Transthyretin Amyloidosis) Therapeutics market

By type

Hereditary Transthyretin Amyloidosis
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis

By treatment

Medicines- Onpattro, Inotersen, Tafamidis
Supportive treatment

By route of administration

Oral
Intravenous
Others

By end users

Hospital pharmacy
Retail pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.